Insmed Inc (INSM)vsOnconetix Inc (ONCO)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
ONCO
Onconetix Inc
$3.03
+428.33%
HEALTHCARE · Cap: $964,110
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 74274% more annual revenue ($606.42M vs $815,370). ONCO leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
ONCO
Avoid30
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -115.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : ONCO
The strongest argument for ONCO centers on Price/Book, Debt/Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : ONCO
The primary concerns for ONCO are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while ONCO is a value play — different risk/reward profiles.
ONCO carries more volatility with a beta of 3.52 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
ONCO generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Onconetix Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Onconetix Inc. is a pioneering biotechnology firm dedicated to transforming cancer care through the advancement of innovative diagnostic and therapeutic solutions. Leveraging its proprietary technology platform, the company focuses on enhancing early detection and personalized treatment strategies across various malignancies, thereby addressing a critical need in oncology. With a robust pipeline that reflects its commitment to addressing the growing demand for effective cancer therapies, Onconetix is well-positioned to make a significant impact on patient outcomes through its cutting-edge research and development initiatives in the rapidly evolving landscape of cancer treatment.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?